Finn
GRAL Healthcare · Diagnostics · Cancer screening · Pre-reimbursement · Thesis updated November 8, 2026

FDA vote clears path but lower prices pressure future margins

01 Running thesis

Balancing demand and price

GRAIL is trying to make Galleri a standard cancer screen. The pitch is simple. It offers one blood test that looks for a shared cancer signal across more than 50 cancer types, then points to where that signal may have started. The hard part is proving that this test should be used and paid for broadly.

The bull case centers on steady demand and a derisked path to FDA approval. Galleri sales volume grew 24% year over year in the third quarter of 2026. A favorable FDA advisory committee vote in September cleared a major hurdle, setting up a potential premarket approval in early 2027. The company also rolled out its first live Epic integration, removing friction for doctors in major health systems.

The bear case highlights weakening unit economics, rising competition, and returning royalties. Management dropped the average selling price to roughly $660 via a price promotion to drive volume ahead of approval. At the same time, the legacy Illumina royalty will resume in late December 2026. This will severely compress gross margins just as prices hit new lows. Adding to this burden, newly filed securities class actions could divert management attention and incur substantial legal costs.

The next year is about proof and cash. Investors need to see average selling prices stabilize and margins survive the returning Illumina royalty. The Medicare MCED law helps the long-term case, but coverage begins in 2029 and still depends on final FDA approval and evidence that payors accept.

Nov 2026→Q3 2026 results highlighted a favorable FDA advisory committee vote, but revealed a lower ASP of $660 and confirmed the return of Illumina royalties in late 2026.
Aug 2026▼The Q2 2026 10-Q disclosed new securities class actions related to the NHS-Galleri trial disclosures, elevating legal risks.
Aug 2026→Q2 2026 results showed Galleri test volume growth moderating to 35% and continued pressure on average selling price. The company successfully closed its $110 million Samsung financing.
May 2026→Q1 2026 sharpened both sides of the story. Galleri volume growth accelerated to 50% year over year, but ASP fell 9%, which raises the price and margin question.
Mar 2026→The 2025 10-K added a better long-term U.S. reimbursement path through the Medicare MCED law. It also added pressure from the NHS-Galleri primary endpoint miss and the extended CFIUS review for Samsung.
Nov 2025→Galleri volume kept growing, but ASP pressure worsened to a 7% decline in Q3 2025. GRAIL also raised capital and announced a Samsung collaboration, while naming new MCED competition.
Aug 2025→Q2 2025 showed 29% Galleri volume growth and a 6% ASP decline. The company also cut investment in non-Galleri programs and gained clarity after the LDT rule decision was not appealed.
May 2025▼Q1 2025 showed 31% Galleri volume growth, but the LDT rule court decision created more regulatory uncertainty. The ruling could lower barriers for competitors.
02 Business model

One test pays the bills

GRAIL makes most of its money by selling the Galleri test in the United States. Galleri is sold today as a Laboratory Developed Test, which means it is offered through a lab pathway rather than as a fully FDA-approved medical device. Customers come through primary care doctors, health systems via direct Epic electronic health record integrations, self-insured employers, and life insurance providers.

In the third quarter of 2026, screening revenue was over 99 percent of total revenue, coming in at $37.3 million. That makes the business simple to understand, but also highly concentrated. If Galleri adoption slows, pricing weakens, or regulators and payors push back, there is no large second business to soften the hit.

A smaller development services business serves biopharma and clinical customers using the company methylation platform. That line was less than 1 percent of third quarter revenue, generating $0.2 million. GRAIL has cut back spending on other product programs so it can focus on Galleri commercialization and the FDA premarket approval submission.

The long-term money path is reimbursement. Today, GRAIL is building demand before broad Medicare coverage. The Medicare MCED law creates a national coverage process for FDA-approved early detection tests, but the benefit starts in 2029. That timing matters because GRAIL may need more capital if cash burn stays high before coverage arrives.

03 Product portfolio

Galleri, plus smaller options

Growth engine

Galleri

Galleri is the core product and the main revenue driver. It is a blood-based multi-cancer early detection test designed to detect a shared cancer signal across more than 50 cancer types and predict where the signal came from.

Option

Galleri FDA PMA program

The PMA path is not a separate test, but it is central to the value of Galleri. FDA approval is needed for the broad reimbursement plan tied to the Medicare MCED law.

Steady

Research-use-only services

GRAIL offers research-use-only services to biopharma partners through its methylation platform. This is much smaller than screening revenue and is part of development services.

Steady

Development services

Development services revenue comes from biopharmaceutical and clinical customers. It made up less than 1 percent of third quarter 2026 revenue.

Option

Diagnostic aid for cancer program

The diagnostic aid for cancer program is not the focus today. GRAIL has substantially decreased investment in this program to direct resources toward Galleri.

Option

Minimal residual disease program

The minimal residual disease program has also been de-prioritized. It may retain future optional value, but the current company story is Galleri.

04 Business segments

Revenue mix is concentrated

Screening Revenue99%growing fast
Development Services Revenue1%declining

The segment mix is from the third quarter of 2026. Screening revenue was over 99 percent of total revenue, making changes in Galleri volume or price the main driver for the whole company.

05 Risk factors

What could break the thesis

ASP drops meet returning royalties

High impact · High odds

Average selling prices fell to roughly $660 due to a price promotion intended to drive volume. Simultaneously, the legacy Illumina royalty resumes in late December 2026. If the company cannot reduce testing costs fast enough, this combination will severely compress gross margins.

We watchGross margin progression in Q1 2027 and management commentary on whether the $660 ASP is structurally permanent.

FDA final label restrictions

High impact · Medium odds

While the FDA advisory committee voted favorably, final premarket approval is expected in early 2027. The FDA could impose strict age bounds or complex shared decision-making requirements on the final label. A weaker label would limit the commercial upside and slow broad adoption.

We watchThe final FDA label requirements upon the expected early Q1 2027 decision.

Securities litigation risk

High impact · Medium odds

Following the NHS-Galleri trial results, new securities class actions were filed against the company in June 2026. These lawsuits allege false and misleading statements. They could lead to substantial legal costs and divert management attention from commercial execution.

We watchLegal filings, settlement reserves, and management commentary on legal expenses in upcoming quarters.

MCED competition pressures share

Medium impact · High odds

Exact Sciences and Guardant Health launched competing early detection products in 2025. Management noted that new tests with aggressive marketing have caused customer confusion. This requires additional sales force education and could pressure Galleri market share.

We watchCompetitor test adoption and management commentary on customer confusion.

Clinical utility doubt after NHS result

High impact · Medium odds

The NHS-Galleri trial showed a reduction in stage 4 cancer diagnoses, but it did not meet the primary endpoint for a statistically significant combined reduction in stage 3 and 4 cancers. That gives payors and regulators a reason to question whether Galleri improves outcomes enough to justify broad use.

We watchFull NHS-Galleri trial data publication and the NHS decision on UK implementation.
06 Quick answers

In one breath

What does GRAIL do?

GRAIL sells Galleri, a blood test that screens for a cancer signal across more than 50 cancer types. The company is focused on proving Galleri should be widely used and reimbursed.

Is Galleri FDA approved?

Galleri is currently sold in the United States as a Laboratory Developed Test. Following a favorable FDA advisory committee vote, the company expects a final premarket approval decision in early 2027.

Why does average selling price matter so much?

Average selling price shows how much GRAIL earns per Galleri test before costs. Volume grew 24% in Q3 2026, but ASP dropped to $660, raising concerns about unit economics as legacy royalties return.

What is the Medicare MCED law?

The law created a Medicare coverage benefit category for multi-cancer early detection tests. For GRAIL, the key point is that coverage starts in 2029 and depends on FDA approval and CMS review.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. GRAIL Q2 2026 10-Q
  2. GRAIL Q3 2026 Earnings Transcript
  3. GRAIL Q1 2026 Form 10-Q
  4. GRAIL 2025 Form 10-K
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near GRAIL Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today